Core Viewpoint - DJS Law Group is investigating claims against Informatica Inc. for potential violations of securities laws following disappointing financial results that led to a significant drop in share price [2]. Investigation Details - The investigation centers on whether Informatica made misleading statements or failed to disclose critical information to investors [2]. - Informatica reported a 3.8% year-over-year decrease in GAAP total revenues and a 2% year-over-year decrease in GAAP subscription revenues for Q4 2024 and the full year 2024 [2]. - Following the release of these results, Informatica's shares fell by more than 21% [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - The article discusses a class action lawsuit against Dow Inc. for alleged violations of the Securities Exchange Act of 1934, with a focus on misleading statements regarding the company's financial health and ability to manage macroeconomic challenges [1][4]. Company Overview - Dow Inc. provides materials science solutions across various sectors, including packaging, infrastructure, mobility, and consumer applications [3]. Allegations of the Lawsuit - The lawsuit claims that Dow and its executives made false or misleading statements about the company's financial flexibility and ability to handle macroeconomic and tariff-related challenges [4]. - It is alleged that Dow understated the negative impacts of competitive pressures, softening global sales, and product oversupply on its business [4]. Financial Performance - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00 due to ongoing weakness in key markets [5]. - Following this downgrade, Dow's stock price fell by over 3% [5]. - On July 24, 2025, Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of approximately $0.17 to $0.18 per share, with net sales of $10.1 billion, a 7.3% year-over-year decline [6]. - Dow's CEO attributed the disappointing results to a challenging earnings environment and announced a dividend cut from $0.70 to $0.35 per share, leading to a stock price drop of over 17% [6]. Legal Process - Investors who purchased Dow securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8].

Core Viewpoint - The Schall Law Firm is investigating Jefferies Financial Group Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its financial exposure to the bankrupt First Brands Group [1][2]. Summary by Relevant Sections - **Company Exposure**: Jefferies disclosed on October 8, 2025, that it has approximately $715 million in exposure to the receivables of First Brands Group, which constitutes about 25% of the trade finance portfolio of its Point Bonita subsidiary [2]. - **Market Reaction**: Following the announcement of this exposure, Jefferies' shares experienced a decline of about 8% on the same day [2].

Core Viewpoint - The Lantheus class action lawsuit alleges that Lantheus Holdings, Inc. and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, leading to significant stock price declines following disappointing financial results [1][4][5][6]. Group 1: Lawsuit Details - The lawsuit, titled Margolis v. Lantheus Holdings, Inc., seeks to represent purchasers of Lantheus securities and claims violations of the Securities Exchange Act of 1934 [1]. - The complaint highlights that Lantheus's key product, Pylarify, is a PET imaging agent used for diagnosing and treating prostate cancer [3]. - Allegations include that Lantheus executives created a false impression of the company's revenue potential while downplaying risks from competition and market dynamics [4]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales, leading to a reduction in full-year growth projections from low-single-digit to flat-to-low single-digit percent growth, resulting in a stock price drop of over 23% [5]. - On August 6, 2025, Lantheus announced further disappointing results, with Pylarify sales down 8.3% year-over-year, and slashed fiscal year 2025 growth projections, causing the stock price to fall nearly 29% [6]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Lantheus securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [7]. - The lead plaintiff can select a law firm to litigate the case and does not need to be the lead plaintiff to share in any potential recovery [7]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [8].

Core Viewpoint - Fluor Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding project costs and financial guidance during a specified class period [1][3]. Group 1: Lawsuit Details - The class action lawsuit, titled Maglione v. Fluor Corporation, allows purchasers of Fluor securities from February 18, 2025, to July 31, 2025, to seek lead plaintiff status by November 14, 2025 [1]. - The lawsuit alleges that Fluor's costs for major infrastructure projects, including the Gordie Howe International Bridge and Texas highways, were increasing due to subcontractor errors, price hikes, and scheduling delays [2][3]. Group 2: Financial Impact - Fluor reported second quarter 2025 non-GAAP earnings per share of $0.43, missing consensus estimates by $0.13, and revenue of $3.98 billion, which is a 5.9% year-over-year decline and $570 million below expectations [4]. - Following the disappointing earnings report, Fluor's stock price dropped by over 27%, attributed to rising costs and reduced capital spending from clients [4]. Group 3: Allegations of Misleading Information - The lawsuit claims that Fluor's financial guidance for fiscal year 2025 was unrealistic and that the company overstated the effectiveness of its risk mitigation strategies while understating the impact of economic uncertainty on its business [3].

Core Viewpoint - A class action lawsuit has been filed against Molina Healthcare, Inc. regarding allegations of securities fraud and unlawful business practices [2][4]. Financial Performance - On July 7, 2025, Molina reported second quarter adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - Molina cut its full year 2025 adjusted earnings per share guidance by 10.2% at the midpoint, revising it from at least $24.50 per share to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97 per share, or 2.9%, closing at $232.61 per share [4]. Subsequent Guidance Adjustments - On July 23, 2025, Molina further reduced its full-year 2025 earnings guidance, now expecting adjusted earnings to be no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [5]. - The company's GAAP net income for the second quarter was reported at $4.75 per diluted share, an 8% decrease year over year [5]. - Molina also cut its full year 2025 GAAP net income guidance by 27% to $912 million, attributing the results to a challenging medical cost trend environment [5]. - Following this news, Molina's stock price dropped by $32.03 per share, or 16.84%, closing at $158.22 per share [5].

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against WPP Plc (“WPP” or the “Company”) (NYSE: WPP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether WPP and certain of its officers and/or directo ...

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tronox Holdings Plc (“Tronox” or the “Company”) (NYSE: TROX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Tronox and certain of its offi ...

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit [1][2]. Financial Performance - On May 7, 2025, Lantheus reported disappointing first-quarter financial results, with sales of its oncology product Pylarify decreasing year-over-year, leading to a reduction in full-year projections [4]. - Following this announcement, Lantheus's stock price dropped by $24.35, or 23.23%, closing at $80.49 per share [5]. - On August 6, 2025, the company announced second-quarter results that also missed expectations, with Pylarify sales falling by 8.3% year-over-year, prompting further reductions in growth expectations and full-year projections [6]. - The stock price fell again by $20.76, or 28.58%, closing at $51.87 per share after the second-quarter announcement [7].

Core Viewpoint - Fortinet, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its business operations and financial performance during the Class Period from November 8, 2024, to August 6, 2025 [1][4]. Financial Performance - On August 6, 2025, Fortinet reported its Q2 2025 financial results, indicating that it was "approximately 40% to 50% of the way through the 2026 firewall upgrade cycle" [2]. - The company provided weaker-than-expected revenue guidance for Q3 2025, projecting revenue between $1.67 billion and $1.73 billion [2]. Stock Price Impact - Following the release of the financial results, Fortinet's stock price dropped by $21.28, or 22%, closing at $75.30 per share on August 7, 2025 [3]. Allegations in the Lawsuit - The lawsuit claims that Fortinet's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [4]. - Specific allegations include: - Misrepresentation of the profitability of the refresh cycle, which was said to consist of old products that were a "small percentage" of the business [4]. - Lack of clarity regarding the number of FortiGate firewalls eligible for upgrades [4]. - Misleading investors about the momentum of the refresh cycle, which was pushed through more quickly than communicated [4]. - Overall, the positive statements made by the company were deemed materially misleading and lacked a reasonable basis [4]. Legal Action Details - Investors who purchased Fortinet common stock during the Class Period can file a lead plaintiff motion by November 21, 2025 [5].